Abstract:Pulmonary fibrosis (PF) is a severe pulmonary disease with limited available therapeutic choices. Recent evidence increasingly points to abnormal lipid metabolism as a critical factor in PF pathogenesis. Our latest research identifies the dysregulation of low-density lipoprotein (LDL) is a new risk factor for PF, contributing to alveolar epithelial and endothelial cell damage, and fibroblast activation. In this study, we first integrative summarize the published literature about lipid metabolite changes found in PF, including phospholipids, glycolipids, steroids, fatty acids, triglycerides, and lipoproteins. We then reanalyze two single-cell RNA-sequencing (scRNA-seq) datasets of PF, and the corresponding lipid metabolomic genes responsible for these lipids' biosynthesis, catabolism, transport, and modification processes are uncovered. Intriguingly, we found that macrophage is the most active cell type in lipid metabolism, with almost all lipid metabolic genes being altered in macrophages of PF. In type 2 alveolar epithelial cells, lipid metabolic differentially expressed genes (DEGs) are primarily associated with the cytidine diphosphate diacylglycerol pathway, cholesterol metabolism, and triglyceride synthesis. Endothelial cells are partly responsible for sphingomyelin, phosphatidylcholine, and phosphatidylethanolamines reprogramming as their metabolic genes are dysregulated in PF. Fibroblasts may contribute to abnormal cholesterol, phosphatidylcholine, and phosphatidylethanolamine metabolism in PF. Therefore, the reprogrammed lipid profiles in PF may be attributed to the aberrant expression of lipid metabolic genes in different cell types. Taken together, these insights underscore the potential of targeting lipid metabolism in developing innovative therapeutic strategies, potentially leading to extended overall survival in individuals affected by PF.

Research Progress of Pericytes in Pulmonary Fibrosis

The Potentially Therapeutic Role of EPAC in Curbing the Process of Idiopathic Pulmonary Fibrosis Via Differential Cellular Pathways

Lung Pericytes in Pulmonary Vascular Physiology and Pathophysiology

Pulmonary fibrosis: pathogenesis and therapeutic strategies

Role of Peripherial Blood Fibrocytes in Pathogenesis of Pulmonary Fibrosis

Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives

Latest progress on the molecular mechanisms of idiopathic pulmonary fibrosis

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies

YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis

Stem cell-based therapy for pulmonary fibrosis

Regulatory T Cells Are a Double-Edged Sword in Pulmonary Fibrosis.

Biomechanical Properties and Cellular Responses in Pulmonary Fibrosis

Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis

Fibroblasts in Pulmonary Hypertension: Roles and Molecular Mechanisms

Pathology of idiopathic pulmonary fibrosis with particular focus on vascular endothelium and epithelial injury and their therapeutic potential

New Therapeutic Approaches Against Pulmonary Fibrosis.

The novel molecular mechanism of pulmonary fibrosis: insight into lipid metabolism from reanalysis of single-cell RNA-seq databases

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis

Advances of Targets and Therapeutic Drugs for Idiopathic Pulmonary Fibrosis